Literature DB >> 25033230

New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseases.

Gaurav Mehta1, Viviana P Ferreira2, Christine Skerka3, Peter F Zipfel4, Nirmal K Banda5.   

Abstract

Complement factor H (CFH) protein is an inhibitor of the alternative pathway of complement (AP) both in the fluid phase and on the surface of host cells. Mouse and human complement factor H-related (CFHR) proteins also belong to the fH family of plasma glycoproteins. The main goal of the current study was to compare the presence of mRNA for two mCFHR proteins in spontaneously developing autoimmune diseases in mice such as dense deposit disease (DDD), diabetes mellitus (DM), basal laminar deposits (BLD), collagen antibody-induced arthrits (CAIA) and systemic lupus erythematosus (SLE). Here we report for the first time that the CFHR-C mRNA was universally absent in the liver from three strains of lupus-prone mice and in a diabetic-prone mouse strain. The mRNA levels (pg/ng) for CFH and CFHR-B in MRL-lpr/lpr, at 9 wks and 23 wks were 707.2±44.4, 54.5±5.75 and 729±252.9, 74.04±22.76, respectively. The mRNA levels for CFH and CFHR-B in NZB/NZW mice, at 9 wks and 54 wks were 579.9±23.8, 58.8±1.41 and 890.3±135.2, 63.30±9.2, respectively. CFHR-C protein was absent in the circulation of MRL-lpr/lpr and NZB/NZW mice before and after the development of lupus. Similarly, mRNA and protein for CFHR-C was universally absent in liver and other organs and in the circulation of NOD mice before and after the development of DM. In contrast, the mRNAs for CFH, CFHR-B and CFHR-C were universally present in the liver from mice with and without DDD, BLD and CAIA. The levels of mRNA for CFHR-B in mice with and without BLD were ∼4 times higher than the mice with lupus. The complete absence of mRNA for CFHR-C in lupus and diabetic-prone strains indicates that polymorphic variation within the mouse CFHR family exists and raises the possibility that such variation contributes to lupus and diabetic phenotypes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Basal laminar deposits; Collagen-induced arthritis; Complement factor H related C; Dense deposit disease; Diabetes mellitus; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2014        PMID: 25033230      PMCID: PMC4157073          DOI: 10.1016/j.molimm.2014.06.028

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  43 in total

1.  Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis.

Authors:  Nirmal K Banda; Gaurav Mehta; Viviana P Ferreira; Claudio Cortes; Matthew C Pickering; Michael K Pangburn; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2013-02-22       Impact factor: 5.422

2.  A hybrid CFHR3-1 gene causes familial C3 glomerulopathy.

Authors:  Talat H Malik; Peter J Lavin; Elena Goicoechea de Jorge; Katherine A Vernon; Kirsten L Rose; Mitali P Patel; Marcel de Leeuw; John J Neary; Peter J Conlon; Michelle P Winn; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

Review 3.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

4.  Complement factor H deficiency accelerates development of lupus nephritis.

Authors:  Lihua Bao; Mark Haas; Richard J Quigg
Journal:  J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 10.121

5.  Dimerization of complement factor H-related proteins modulates complement activation in vivo.

Authors:  Elena Goicoechea de Jorge; Joseph J E Caesar; Talat H Malik; Mitali Patel; Matthew Colledge; Steven Johnson; Svetlana Hakobyan; B Paul Morgan; Claire L Harris; Matthew C Pickering; Susan M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

Review 6.  Human complement control and complement evasion by pathogenic microbes--tipping the balance.

Authors:  Peter F Zipfel; Teresia Hallström; Kristian Riesbeck
Journal:  Mol Immunol       Date:  2013-06-28       Impact factor: 4.407

7.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 8.  Murine models of systemic lupus erythematosus.

Authors:  Daniel Perry; Allison Sang; Yiming Yin; Ying-Yi Zheng; Laurence Morel
Journal:  J Biomed Biotechnol       Date:  2011-02-14

9.  C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.

Authors:  Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Julie A Vrana; Samih H Nasr; Jason D Theis; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2012-08       Impact factor: 10.612

Review 10.  C3 glomerulonephritis and CFHR5 nephropathy.

Authors:  Daniel P Gale; Patrick H Maxwell
Journal:  Nephrol Dial Transplant       Date:  2012-11-02       Impact factor: 5.992

View more
  9 in total

Review 1.  Thinking bedside at the bench: the NOD mouse model of T1DM.

Authors:  James C Reed; Kevan C Herold
Journal:  Nat Rev Endocrinol       Date:  2015-01-27       Impact factor: 43.330

2.  Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins.

Authors:  Alexandra H Antonioli; Janice White; Frances Crawford; Brandon Renner; Kevin J Marchbank; Jonathan P Hannan; Joshua M Thurman; Philippa Marrack; V Michael Holers
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

Review 3.  Complement in Lupus Nephritis: New Perspectives.

Authors:  Lihua Bao; Patrick N Cunningham; Richard J Quigg
Journal:  Kidney Dis (Basel)       Date:  2015-06-30

Review 4.  The Rational Use of Complement Inhibitors in Kidney Diseases.

Authors:  Fadi Fakhouri; Nora Schwotzer; Déla Golshayan; Véronique Frémeaux-Bacchi
Journal:  Kidney Int Rep       Date:  2022-03-04

5.  Deficiency of Mouse FHR-1 Homolog, FHR-E, Accelerates Sepsis, and Acute Kidney Injury Through Enhancing the LPS-Induced Alternative Complement Pathway.

Authors:  Xiangru Li; Zhenhua Hao; Xiaorong Liu; Wei Li
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 6.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

7.  Complement Regulator FHR-3 Is Elevated either Locally or Systemically in a Selection of Autoimmune Diseases.

Authors:  Nicole Schäfer; Antje Grosche; Joerg Reinders; Stefanie M Hauck; Richard B Pouw; Taco W Kuijpers; Diana Wouters; Boris Ehrenstein; Volker Enzmann; Peter F Zipfel; Christine Skerka; Diana Pauly
Journal:  Front Immunol       Date:  2016-11-28       Impact factor: 7.561

Review 8.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

9.  The Murine Factor H-Related Protein FHR-B Promotes Complement Activation.

Authors:  Marcell Cserhalmi; Ádám I Csincsi; Zoltán Mezei; Anne Kopp; Mario Hebecker; Barbara Uzonyi; Mihály Józsi
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.